Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 9Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Neoplasms, Male 1

Interventions

Dexamethasone 4pomalidomide 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gallium 68 PSMA-11 1copanlisib 1carfilzomib 1belinostat 1belantamab mafodotin 1Zoledronic Acid 1Topotecan 1Tablets 1Sitagliptin Phosphate 1Pluvicto 1Paclitaxel 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Renal Insufficiency × Pluvicto × Clear all
NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡